Enovis (NYSE:ENOV) Upgraded at Zacks Research

Zacks Research upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a strong-buy rating in a research note published on Wednesday,Zacks.com reports.

A number of other equities analysts also recently commented on ENOV. Canaccord Genuity Group reduced their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Wells Fargo & Company lifted their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. BTIG Research boosted their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Evercore reissued an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, UBS Group restated a “buy” rating and issued a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.43.

Enovis Stock Up 0.7%

Enovis stock opened at $24.49 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The firm has a market cap of $1.40 billion, a P/E ratio of -1.18 and a beta of 1.46. The business has a fifty day moving average of $24.10 and a two-hundred day moving average of $28.05. Enovis has a twelve month low of $21.00 and a twelve month high of $40.69.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Oliver Engert acquired 1,000 shares of Enovis stock in a transaction on Friday, February 27th. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. The trade was a 2.35% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 2,250 shares of company stock worth $56,545 in the last quarter. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds have recently modified their holdings of the stock. McIlrath & Eck LLC grew its holdings in Enovis by 6.9% during the third quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock worth $167,000 after acquiring an additional 357 shares during the period. Farther Finance Advisors LLC lifted its holdings in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares during the period. Teacher Retirement System of Texas boosted its position in Enovis by 6.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after purchasing an additional 495 shares in the last quarter. Amalgamated Bank boosted its position in Enovis by 3.6% in the 3rd quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after purchasing an additional 585 shares in the last quarter. Finally, Heritage Family Offices LLP grew its stake in shares of Enovis by 8.9% during the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock worth $231,000 after purchasing an additional 620 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.